Company News
Guggenheim Picks Abivax as Top Biotech Bet
Guggenheim names Abivax (NASDAQ:ABVX) its leading biotechnology pick ahead of a Phase III ABTECT data readout at end‑June.
Management will disclose topline safety, exposure‑adjusted incidence rates, a
